Vaxcyte, Inc. $PCVX Shares Sold by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. lowered its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 92.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,898 shares of the company’s stock after selling 1,081,982 shares during the period. Nan Fung Trinity HK Ltd. owned about 0.06% of Vaxcyte worth $5,286,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. New York Life Investment Management LLC raised its position in shares of Vaxcyte by 19.7% during the third quarter. New York Life Investment Management LLC now owns 21,011 shares of the company’s stock worth $1,196,000 after purchasing an additional 3,451 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Vaxcyte by 6.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 7,808 shares of the company’s stock valued at $438,000 after purchasing an additional 444 shares in the last quarter. Candriam S.C.A. grew its position in shares of Vaxcyte by 115.0% in the 3rd quarter. Candriam S.C.A. now owns 447,260 shares of the company’s stock valued at $25,542,000 after purchasing an additional 239,206 shares during the period. Covestor Ltd grew its position in shares of Vaxcyte by 31.1% in the 3rd quarter. Covestor Ltd now owns 939 shares of the company’s stock valued at $53,000 after purchasing an additional 223 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Vaxcyte in the 3rd quarter valued at approximately $1,270,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $64.69 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.56 and a current ratio of 4.56. The stock’s 50-day moving average is $62.19 and its 200-day moving average is $57.60. Vaxcyte, Inc. has a one year low of $42.40 and a one year high of $90.75.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($1.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.11) by $0.12. During the same period in the prior year, the company earned ($1.56) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -7.51 earnings per share for the current year.

Insider Buying and Selling

In other news, CAO Elvia Cowan sold 19,000 shares of Vaxcyte stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $86.74, for a total value of $1,648,060.00. Following the sale, the chief accounting officer directly owned 27,860 shares in the company, valued at $2,416,576.40. This trade represents a 40.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jim Wassil sold 18,000 shares of Vaxcyte stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $86.74, for a total transaction of $1,561,320.00. Following the completion of the sale, the executive vice president owned 145,435 shares in the company, valued at $12,615,031.90. This trade represents a 11.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 50,692 shares of company stock valued at $4,032,875. Insiders own 3.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PCVX. Guggenheim increased their target price on Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Bank of America cut their price target on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research note on Monday, September 28th. BTIG Research reiterated a “buy” rating and issued a $89.00 price target on shares of Vaxcyte in a report on Monday, October 5th. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Needham & Company LLC increased their price objective on shares of Vaxcyte from $110.00 to $122.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $110.50.

Vaxcyte Profile

Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.